Phase‑3 trial of recombinant human alkaline phosphatase for patients with sepsis‑associated acute kidney injury (REVIVAL)
View publication
AM-PHARMA TO PRESENT DATA FROM PHASE 3 REVIVAL STUDY AT UPCOMING SCIENTIFIC CONFERENCES
Principal investigator Professor Peter Pickkers to present data at ISICEM on March 21st in Brussels and at the AKI & CRRT conference on March 29th in San Diego A significant reduction in major adverse kidney events by day 90 and no difference in 28-day all-cause mortality was observed after review of the data from all […]
Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury
You can read the whole publication by clicking on this button View publication
Effects of a human recombinant alkaline phosphatase during impaired mitochondrial function in human renal proximal tubule epithelial cells
View publication
Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injury
View publication
Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humans
View publication
Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphatase
View publication
Alkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and adenosine triphosphate
View publication
